June 4, 2026
Supporting Innovation in Friedrich Ataxia Clinical Research
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Register Your Interest
English
The Doherty Clinical Trials team are excited to announce that we have been awarded a grant from the Prior Family Foundation in recognition of our ongoing commitment to advancing innovative medical research.
The Doherty Clinical Trials team are grateful to the Prior Family Foundation for their support, which plays a crucial role in our efforts to combat infectious diseases locally and globally
Recently announced clinical results show positive data as part of the ongoing PHASE1/2 RESTORE-FA trial
Doherty Clinical Trials Limited is proud to announce the commencement of the CHIVAS-M1 study (Controlled Human Infection for Vaccination Against Streptococcus pyogenes M1UK), which will help drive medical research and development of a vaccine against Streptococcus pyogenes, otherwise known as Strep A.
Senior Lab Manager, Vanessa Mollard represented Doherty Clinical Trials at the forum in Canberra
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}